10-K/A: Apimeds Pharmaceuticals US, Inc. Files Amended 10-K to Correct Disclosure on Internal Controls

Apimeds Pharmaceuticals US, Inc. files an amendment to its annual report to disclose that its disclosure controls and procedures were not effective as of December 31, 2024, due to material weaknesses in internal controls over financial reporting.

Summary

• Apimeds Pharmaceuticals US, Inc. is filing an amendment (Form 10-K/A) to its original Annual Report on Form 10-K for the year ended December 31, 2024.
• The amendment corrects disclosure in Part II, Item 9A regarding Controls and Procedures, indicating that the company's disclosure controls and procedures were not effective as of December 31, 2024.
• The company identified material weaknesses in its internal control over financial reporting.
• Specifically, there were insufficient documented procedures or control activities to support a reliable financial reporting process, including an absence of controls over journal entries, segregation of duties, and reconciliations.
• Management concluded that the company's internal control over financial reporting was not effective as of December 31, 2024, based on their assessment using the COSO framework.
• The amendment also includes new certifications from the CEO and CFO.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the disclosure of material weaknesses in internal controls, which raises concerns about the reliability of financial reporting.

Positives

• The company is taking steps to correct deficiencies in its internal controls and procedures.
• The company is transparently disclosing the material weaknesses identified.

Negatives

• The company's disclosure controls and procedures were not effective as of December 31, 2024.
• Material weaknesses exist in the company's internal control over financial reporting.
• There is an absence of controls over the review and approval of journal entries, segregation of duties, reconciliations, and other fundamental accounting processes.

Risks

• The material weaknesses in internal control over financial reporting could lead to material misstatements in the company's financial statements.
• The company's ability to reliably report financial data is compromised.
• Failure to remediate these weaknesses could result in regulatory scrutiny or legal action.

Future Outlook

The Company continues to review its disclosure controls and procedures, including its internal control over financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that the Company's systems evolve with its business.

Management Comments

• Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of December 31, 2024 in providing reasonable assurance of achieving the desired control objectives.
• Based on our assessment under the criteria described above, we have concluded that our internal control over financial reporting was not effective as of December 31, 2024.

Industry Context

Many companies, especially smaller reporting companies and emerging growth companies, face challenges in establishing and maintaining effective internal controls over financial reporting. This announcement highlights the importance of robust internal controls and the potential consequences of material weaknesses.

Comparison to Industry Standards

• Companies like Enron and WorldCom faced similar issues with internal controls, leading to significant financial restatements and reputational damage.
• The Sarbanes-Oxley Act (SOX) was enacted to strengthen corporate governance and internal controls, setting a higher standard for financial reporting.
• Compared to larger, well-established pharmaceutical companies with mature internal control systems, Apimeds Pharmaceuticals US, Inc., as a smaller company, may face resource constraints in implementing and maintaining comprehensive controls.

Stakeholder Impact

• Shareholders may be concerned about the reliability of the company's financial reporting.
• Employees involved in financial reporting may need to implement new or improved controls.
• Creditors may reassess the company's creditworthiness due to the identified weaknesses.

Next Steps

• The Company continues to review its disclosure controls and procedures, including its internal control over financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that the Company's systems evolve with its business.

Key Dates

Keywords

internal controls, material weakness, disclosure controls, financial reporting, Form 10-K/A, Apimeds Pharmaceuticals, amendment